A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion

Cell Transplantation

Volumn 22, Issue 3, 2013, Pages 423-436

  Xinaris, Christodoulos ^a   Morigi, M ^a   Benedetti, V ^a   Imberti, B ^a   Fabricio, A S ^b   Squarcina, E ^c   Benigni, A ^a   Gagliardini, E ^a   Remuzzi, G ^a,d  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Regional Center for Biomarkers ABO Foundation   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d OSPEDALI RIUNITI   (Italy)

Author keywords

Acute kidney injury (AKI); Insulin like growth factor 1 (IGF 1); Kidney repair; Mesenchymal stem cells (MSCs); Migration

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; IN VITRO STUDY; KIDNEY FUNCTION; KIDNEY STRUCTURE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RENAL PROTECTION; TISSUE REPAIR;

ACUTE KIDNEY INJURY; ANIMALS; BONE MARROW CELLS; CELL MOVEMENT; CELLS, CULTURED; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INSULIN-LIKE GROWTH FACTOR I; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; RECEPTORS, CXCR4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877311784     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368912X653246     Document Type: Article

References (48)

1. Abe, H.; Ina, K.; Kitamura, H.; Sumiyoshi, H.; Tatsukawa, S.; Yoshioka, H.; Fujikura, Y. Role of the CXCL12/CXCR4 axis in milky spots of rats bearing ascitic-type hepatoma. Anat. Sci. Int. 84:226-236; 2009.
2. Anjos-Afonso, F.; Siapati, E. K.; Bonnet, D. In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J. Cell Sci. 117:5655-5664; 2004.
3. Ankrum, J.; Karp, J. M. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol. Med. 16: 203-209; 2010.
4. Assis, A. C.; Carvalho, J. L.; Jacoby, B. A.; Ferreira, R. L.; Castanheira, P.; Diniz, S. O.; Cardoso, V. N.; Goes, A. M.; Ferreira, A. J. Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant. 19:219-230; 2010.
5. Brenner, S.; Whiting-Theobald, N.; Kawai, T.; Linton, G. F.; Rudikoff, A. G.; Choi, U.; Ryser, M. F.; Murphy, P. M.; Sechler, J. M.; Malech, H. L. CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. Stem Cells 22:1128-1133; 2004.
6. Chamberlain, G.; Wright, K.; Rot, A.; Ashton, B.; Middleton, J. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: Comparison with human. PLoS One 3:e2934; 2008.
7. Chen, S. L.; Fang, W. W.; Ye, F.; Liu, Y. H.; Qian, J.; Shan, S. J.; Zhang, J. J.; Chunhua, R. Z.; Liao, L. M.; Lin, S.; Sun, J. P. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardiol. 94:92-95; 2004.
8. Cheng, Z. O., L.; Zhou, X.; Li, F.; Jia, X.; Zhang, Y.; Liu, X.; Li, Y.; Ward, C. A.; Melo, L. G.; Kong, D. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol. Ther. 16:571-579; 2008.
9. Gooch, A.; Doty, J.; Flores, J.; Swenson, L.; Toegel, F. E.; Reiss, G. R.; Lange, C.; Zander, A. R.; Hu, Z.; Poole, S.; Zhang, P.; Westenfelder, C. Initial report on a phase I clinical trial: Prevention and treatment of postoperative acute kidney injury with allogeneic mesenchymal stem cells in patients who require on-pump cardiac surgery. Cell. Ther. Transplant. 1:31-35; 2008.
10. Hagiwara, M.; Shen, B.; Chao, L.; Chao, J. Kallikreinmodified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum. Gene Ther. 19:807-819; 2008.
11. Hare, J. M.; Traverse, J. H.; Henry, T. D.; Dib, N.; Strumpf, R. K.; Schulman, S. P.; Gerstenblith, G.; DeMaria, A. N.; Denktas, A. E.; Gammon, R. S.; Hermiller, J. B. J.; Reisman, M. A.; Schaer, G. L.; Sherman, W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 54:2277-2286; 2009.
12. Honczarenko, M.; Le, Y.; Swierkowski, M.; Ghiran, I.; Glodek, A. M.; Silberstein, L. E. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24:1030-1041; 2006.
13. Horwitz, E. M.; Gordon, P. L.; Koo, W. K.; Marx, J. C.; Neel, M. D.; McNall, R. Y.; Muul, L.; Hofmann, T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc. Natl. Acad. Sci. USA 99:8932-8937; 2002.
14. Hung, S. C.; Pochampally, R. R.; Chen, S. C.; Hsu, S. C.; Prockop, D. J. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 25:2363-2370; 2007.
15. Hung, S. C.; Pochampally, R. R.; Hsu, S. C.; Sanchez, C.; Chen, S. C.; Spees, J.; Prockop, D. J. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2:e416; 2007.
16. Imberti, B.; Morigi, M.; Tomasoni, S.; Rota, C.; Corna, D.; Longaretti, L.; Rottoli, D.; Valsecchi, F.; Benigni, A.; Wang, J.; Abbate, M.; Zoja, C.; Remuzzi, G. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J. Am. Soc. Nephrol. 18:2921-2928; 2007.
17. Karp, J. M.; Leng Teo, G. S. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 4:206-216; 2009.
18. Koc, O. N.; Day, J.; Nieder, M.; Gerson, S. L.; Lazarus, H. M.; Krivit, W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 30:215-222; 2002.
19. Kollet, O.; Petit, I.; Kahn, J.; Samira, S.; Dar, A.; Peled, A.; Deutsch, V.; Gunetti, M.; Piacibello, W.; Nagler, A.; Lapidot, T. Human CD34(+) CXCR4(-) sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood 100:2778-2786; 2002.
20. Kraitchman, D. L.; Tatsumi, M.; Gilson, W. D.; Ishimori, T.; Kedziorek, D.; Walczak, P.; Segars, W. P.; Chen, H. H.; Fritzges, D.; Izbudak, I.; Young, R. G.; Marcelino, M.; Pittenger, M. F.; Solaiyappan, M.; Boston, R. C.; Tsui, B. M.; Wahl, R. L.; Bulte, J. W. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 112:1451-1461; 2005.
21. Kumar, S.; Ponnazhagan, S. Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. FASEB J. 21:3917-3927; 2007.
22. Lauffenburger, D. A.; Horwitz, A. F. Cell migration: A physically integrated molecular process. Cell 84:359-369; 1996.
23. Le Blanc, K.; Frassoni, F.; Ball, L.; Locatelli, F.; Roelofs, H.; Lewis, I.; Lanino, E.; Sundberg, B.; Bernardo, M. E.; Remberger, M.; Dini, G.; Egeler, R. M.; Bacigalupo, A.; Fibbe, W.; Ringden, O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371:1579-1586; 2008.
24. Le Blanc, K.; Rasmusson, I.; Sundberg, B.; Gotherstrom, C.; Hassan, M.; Uzunel, M.; Ringden, O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441; 2004.
25. Li, Y.; Yu, X.; Lin, S.; Li, X.; Zhang, S.; Song, Y. H. Insulin-like growth factor 1 enhances the migratory capacity of mesenchymal stem cells. Biochem. Biophys. Res. Commun. 356:780-784; 2007.
26. Majumdar, M. K.; Thiede, M. A.; Haynesworth, S. E.; Bruder, S. P.; Gerson, S. L. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J. Hematother. Stem Cell Res. 9:841-848; 2000.
27. Meyer, G. P.; Wollert, K. C.; Lotz, J.; Steffens, J.; Lippolt, P.; Fichtner, S.; Hecker, H.; Schaefer, A.; Arseniev, L.; Hertenstein, B.; Ganser, A.; Drexler, H. Intracoronary bone marrow cell transfer after myocardial infarction: Eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113:1287-1294; 2006.
28. Mills, C. Osiris therapeutics announces preliminary results for prochymal phase III GvHD trials. Press Release; 2009. [cited 1 November, 2009]; available from: http://investor. osiris.com/releasedetail.cfm?ReleaseID=407404.
29. Morigi, M.; Imberti, B.; Zoja, C.; Corna, D.; Tomasoni, S.; Abbate, M.; Rottoli, D.; Angioletti, S.; Benigni, A.; Perico, N.; Alison, M.; Remuzzi, G. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J. Am. Soc. Nephrol. 15:1794-1804; 2004.
30. Morigi, M.; Introna, M.; Imberti, B.; Corna, D.; Abbate, M.; Rota, C.; Rottoli, D.; Benigni, A.; Perico, N.; Zoja, C.; Rambaldi, A.; Remuzzi, A.; Remuzzi, G. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 26:2075-2082; 2008.
31. Morigi, M.; Rota, C.; Montemurro, T.; Montelatici, E.; Lo Cicero, V.; Imberti, B.; Abbate, M.; Zoja, C.; Cassis, P.; Longaretti, L.; Rebulla, P.; Introna, M.; Capelli, C.; Benigni, A.; Remuzzi, G.; Lazzari, L. Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells 28:513-522; 2010.
32. Muschler, G. F.; Nakamoto, C.; Griffith, L. G. Engineering principles of clinical cell-based tissue engineering. J. Bone Joint Surg. Am. 86-A:1541-1558; 2004.
33. Phinney, D. G.; Prockop, D. J. Concise review: Mesenchymal stem/multipotent stromal cells: The state of transdifferentiation and modes of tissue repair-current views. Stem Cells 25:2896-2902; 2007.
34. Pittenger, M. F.; Mackay, A. M.; Beck, S. C.; Jaiswal, R. K.; Douglas, R.; Mosca, J. D.; Moorman, M. A.; Simonetti, D. W.; Craig, S.; Marshak, D. R. Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147; 1999.
35. Ponte, A. L.; Marais, E.; Gallay, N.; Langonne, A.; Delorme, B.; Herault, O.; Charbord, P.; Domenech, J. The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. Stem Cells 25:1737-1745; 2007.
36. Sackstein, R.; Merzaban, J. S.; Cain, D. W.; Dagia, N. M.; Spencer, J. A.; Lin, C. P.; Wohlgemuth, R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 14:181-187; 2008.
37. Schmidt, A.; Ladage, D.; Schinkothe, T.; Klausmann, U.; Ulrichs, C.; Klinz, F. J.; Brixius, K.; Arnhold, S.; Desai, B.; Mehlhorn, U.; Schwinger, R. H.; Staib, P.; Addicks, K.; Bloch, W. Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells 24:1750-1758; 2006.
38. Segers, V. F.; Van Riet, I.; Andries, L. J.; Lemmens, K.; Demolder, M. J.; De Becker, A. J.; Kockx, M. M.; De Keulenaer, G. W. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: Activators and mechanisms. Am. J. Physiol. Heart Circ. Physiol. 290:H1370-1377; 2006.
39. Shi, H.; Patschan, D.; Dietz, G. P.; Bahr, M.; Plotkin, M.; Goligorsky, M. S. Glial cell line-derived neurotrophic growth factor increases motility and survival of cultured mesenchymal stem cells and ameliorates acute kidney injury. Am. J. Physiol. Renal Physiol. 294:F229-F235; 2008.
40. Singh, G. A possible cellular mechanism of cisplatin-induced nephrotoxicity. Toxicology 58:71-80; 1989.
41. Togel, F.; Hu, Z.; Weiss, K.; Isaac, J.; Lange, C.; Westenfelder, C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiationindependent mechanisms. Am. J. Physiol. Renal Physiol. 289:F31-F42; 2005.
42. Togel, F.; Isaac, J.; Hu, Z.; Weiss, K.; Westenfelder, C. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int. 67:1772-1784; 2005.
43. Togel, F.; Weiss, K.; Yang, Y.; Hu, Z.; Zhang, P.; Westenfelder, C. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am. J. Physiol. Renal Physiol. 292:F1626-F1635; 2007.
44. Toma, C.; Wagner, W. R.; Bowry, S.; Schwartz, A.; Villanueva, F. Fate of culture-expanded mesenchymal stem cells in the microvasculature: In vivo observations of cell kinetics. Circ. Res. 104:398-402; 2009.
45. Xinaris, C.; Imberti, B.; Remuzzi, G.; Morigi, M. Bone marrow mesenchymal stem cells in organ repair and strategies to optimize their efficacy. In: Goligorsky, M. S., ed. Regenerative Nephrology. London, UK: Academic Press; 2010:299-312.
46. Yagi, H.; Soto-Gutierrez, A.; Kitagawa, Y.; Tilles, A. W.; Tompkins, R. G.; Yarmush, M. L. Bone marrow mesenchymal stromal cells attenuate organ injury induced by LPS and burn. Cell Transplant. 19:823-830; 2010.
47. Yew, T. L.; Hung, Y. T.; Li, H. Y.; Chen, H. W.; Chen, L. L.; Tsai, K. S.; Chiou, S. H.; Chao, K. C.; Huang, T. F.; Chen, H. L.; Hung, S. C. Enhancement of wound healing by human multipotent stromal cell conditioned medium: The paracrine factors and p38MAPK activation. Cell Transplant. 20:693-706; 2011.
48. Zhang, Y.; Foudi, A.; Geay, J. F.; Berthebaud, M.; Buet, D.; Jarrier, P.; Jalil, A.; Vainchenker, W.; Louache, F. Intracellular localization and constitutive endocytosis of CXCR4 in human CD34+ hematopoietic progenitor cells. Stem Cells 22:1015-1029; 2004.